

Paula L Mcclean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577497/publications.pdf>

Version: 2024-02-01

33
papers

3,193
citations

331259

21
h-index

414034

32
g-index

42
all docs

42
docs citations

42
times ranked

3985
citing authors

#	ARTICLE	IF	CITATIONS
1	Practical Strategies for Extreme Missing Data Imputation in Dementia Diagnosis. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 818-827.	3.9	18
2	Alzheimer's Disease Assessments Optimized for Diagnostic Accuracy and Administration Time. IEEE Journal of Translational Engineering in Health and Medicine, 2022, 10, 1-9.	2.2	6
3	Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank. Endocrinology, Diabetes and Metabolism, 2022, , e00326.	1.0	1
4	Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: A longitudinal retrospective study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12122.	1.8	28
5	Computational Neurology: Computational Modeling Approaches in Dementia. , 2021, , 81-89.		2
6	An Early Stage Researcher's Primer on Systems Medicine Terminology. Network and Systems Medicine, 2021, 4, 2-50.	2.7	9
7	Alterations of plasma endocannabinoid levels in MCI and dementia patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
8	Shaping a data-driven era in dementia care pathway through computational neurology approaches. BMC Medicine, 2020, 18, 398.	2.3	24
9	Multi-time-point data preparation robustly reveals MCI and dementia risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12116.	1.2	4
10	Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease. Neuropharmacology, 2020, 174, 108118.	2.0	14
11	Early Stage Glycosylation Biomarkers in Alzheimer's Disease. Medicines (Basel, Switzerland), 2019, 6, 92.	0.7	22
12	A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. Expert Systems With Applications, 2019, 130, 157-171.	4.4	73
13	Sustained high-fat diet modulates inflammation, insulin signalling and cognition in mice and a modified xenin peptide ameliorates neuropathology in a chronic high-fat model. Diabetes, Obesity and Metabolism, 2018, 20, 1166-1175.	2.2	49
14	Inflammation, insulin signaling and cognitive function in aged APP/PS1 mice. Brain, Behavior, and Immunity, 2018, 70, 423-434.	2.0	56
15	Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition. Neural Regeneration Research, 2018, 13, 1719.	1.6	59
16	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. Metabolites, 2017, 7, 28.	1.3	102
17	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. Neurobiology of Aging, 2016, 38, 151-163.	1.5	102
18	Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behavioural Brain Research, 2015, 293, 96-106.	1.2	94

#	ARTICLE	IF	CITATIONS
19	Restoration of Cerebral and Systemic Microvascular Architecture in $\text{APP}/\text{PS}1$ Transgenic Mice Following Treatment with Liraglutide. <i>Microcirculation</i> , 2015, 22, 133-145.	1.0	40
20	Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. <i>Neuropharmacology</i> , 2014, 76, 57-67.	2.0	267
21	Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2014, 86, 241-258.	2.0	130
22	The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid- β Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2013, 15, 102-114.	1.8	134
23	A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APP ^{swe} /PS1 ^{E9} Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e54769.	1.1	76
24	Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2012, 33, 265-276.	1.5	144
25	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated $\text{A}\beta$ oligomers. <i>Journal of Clinical Investigation</i> , 2012, 122, 1339-1353.	3.9	697
26	The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 6587-6594.	1.7	559
27	Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2010, 630, 158-162.	1.7	163
28	Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. <i>Biological Chemistry</i> , 2009, 390, 75-80.	1.2	34
29	GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E1746-E1755.	1.8	211
30	Effects of Subchronic Treatment With the Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist, N-AcGIP, on Glucose Homeostasis in Streptozotocin-Induced Diabetes. <i>Pancreas</i> , 2007, 35, 73-79.	0.5	5
31	Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 572-579.	1.7	29
32	Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. <i>Journal of Peptide Science</i> , 2007, 13, 400-405.	0.8	20
33	Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. <i>Experimental Gerontology</i> , 2007, 42, 296-300.	1.2	10